A novel self-assembled epitope peptide nanoemulsion vaccine targeting nasal mucosal epithelial cell for reinvigorating CD8+ T cell immune activity and inhibiting tumor progression

Epitope peptides are not suitable for nasal administration immunity due to their poor immunogenicity and low delivery efficiency. Here, we reported an intranasal self-assembled nanovaccine (I-OVA NE), which was loaded with the IKVAV-OVA257–264 (I-OVA), a laminin peptide (Ile-Lys-Val-ala-Val, IKVAV) OVA257–264 epitope conjugated peptide. This I-OVA at concentration of 4 mg/mL showed average particle size 30.37 ± 2.49 nm, zeta potential −16.67 1.76 mV, encapsulation rate 84.07 7.59%. Moreover, mucin did alter its stability (size, PdI potential). And it also had no obvious acute pathological changes neither in mucosa nor lung tissues after administration. Meanwhile, antigen uptake NE promoted, residence time prolonged vivo. Besides, this obviously higher than that free (P < 0.001) blocking by integrin antibody, suggesting binding IKVAV is involved uptake. Importantly, enhanced peptide-specific CD8+T cells exhibiting OVA257–264-specific CTL activity Th1 immune response, leading induction protective E.G7-OVA tumor-bearing mice. Overall, these data indicate can be applicable strategy tumor vaccine development.